Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy

BACKGROUND: Personalised medicine and targeted therapy have revolutionised cancer treatment. However, most patients develop drug resistance and relapse after showing an initial treatment response. Two theories have been postulated; either secondary resistance mutations develop de novo during therapy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Heydt, Carina, Kumm, Niklas, Fassunke, Jana, Künstlinger, Helen, Ihle, Michaela Angelika, Scheel, Andreas, Schildhaus, Hans-Ulrich, Haller, Florian, Büttner, Reinhard, Odenthal, Margarete, Wardelmann, Eva, Merkelbach-Bruse, Sabine
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4404105/
https://ncbi.nlm.nih.gov/pubmed/25886408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1311-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados